menu
    • menu
    [{"orgOrder":0,"company":"Glaukos","sponsor":"Celanese","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Glaukos \/ Celanese","highestDevelopmentStatusID":"15","companyTruncated":"Glaukos \/ Celanese"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Celanese","sponsor":"Glaukos","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Agreement","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Celanese","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Celanese \/ Glaukos","highestDevelopmentStatusID":"10","companyTruncated":"Celanese \/ Glaukos"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glaukos","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase III","graph3":"Glaukos","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intraocular Implant","sponsorNew":"Glaukos \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"Glaukos \/ Inapplicable"},{"orgOrder":0,"company":"Glenmark Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Glenmark Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Glenmark Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Glenmark Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase I","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Ocular Therapeutix","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Phase II","graph3":"Ocular Therapeutix","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Intracameral Implant","sponsorNew":"Ocular Therapeutix \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Ocular Therapeutix \/ Inapplicable"},{"orgOrder":0,"company":"Lupin Ltd","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Other Small Molecule","year":"2024","type":"Inapplicable","leadProduct":"Travoprost","moa":"FP receptor","graph1":"Ophthalmology","graph2":"Approved FDF","graph3":"Lupin Ltd","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Solution","sponsorNew":"Lupin Ltd \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Lupin Ltd \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Travoprost

    Menu

    Travoprost

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Glenmark Pharmaceuticals

                            India arrow
                            Cophex
                            Not Confirmed

                            Glenmark Pharmaceuticals

                            India arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Glenmark Pharma Launches Travoprost Ophthalmic Solution USP

                            Details : Travoprost is a prostaglandin analog. It is indicated for the treatment of patients with open-angle glaucoma or ocular hypertension.

                            Product Name : Travatan Z

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            November 27, 2024

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Lupin Ltd

                            India arrow
                            Cophex
                            Not Confirmed

                            Lupin Ltd

                            India arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Lupin Receives Approval from U.S. FDA for Travoprost Ophthalmic Solution USP

                            Details : Travoprost is a prostaglandin analog. It is indicated for the treatment of patients with open-angle glaucoma or ocular hypertension.

                            Product Name : Travatan Z-Generic

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 05, 2024

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Ocular Therapeutix

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Ocular Therapeutix

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Ocular Therapeutix™ Reports Positive Phase 2 PAXTRAVA™ Glaucoma Data at ASCRS Meeting

                            Details : Paxtrava (travoprost intracameral implant) is a prostaglandin analog. It is being evaluated for the treatment of patients with open-angle glaucoma or ocular hypertension.

                            Product Name : Paxtrava

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 04, 2024

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Glaukos

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)

                            Details : iDose® TR (travoprost intracameral implant) is a prostaglandin analog. It s indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension.

                            Product Name : iDose TR

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            March 04, 2024

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Glaukos

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Celanese

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Celanese Launches Glaukos' iDose TR Using VitalDose EVA

                            Details : iDose® TR (Travoprost Intracameral Implant) is a prostaglandin analog. It s indicated for the reduction of intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension

                            Product Name : iDose TR

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 29, 2024

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Celanese

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Glaukos

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)

                            Details : iDose TR (travoprost intracameral implant) is a prostaglandin analog indicated for the reduction of intraocular pressure (IOP) in patients with ocular hypertension (OHT) or open-angle glaucoma (OAG).

                            Product Name : iDose TR

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            December 14, 2023

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Approved FDF

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Glaukos

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability

                            Details : iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to lower intraocular pressure. Once all the travoprost is released, the iDose TR is then removed and replaced with a new iDose TR, thus offers a dropless alternative to dail...

                            Product Name : iDose TR

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            October 01, 2023

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Glaukos

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Glaukos Announces FDA Acceptance of NDA Submission for iDose TR

                            Details : iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to lower intraocular pressure. Once all the travoprost is released, the iDose TR is then removed and replaced with a new iDose TR, thus offers a dropless alternative to dail...

                            Product Name : iDose TR

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            May 05, 2023

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Celanese

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Celanese

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Glaukos

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Celanese Announces Agreement with Glaukos Corporation for Sustained Release Glaucoma Treatment

                            Details : Glaukos will supply its VitalDose® Drug Delivery Platform for use as a component in Glaukos’ iDose® TR (travoprost), a micro-invasive intraocular implant designed to lower intraocular pressure in patients with primary open-angle glaucoma or ocular hy...

                            Product Name : iDose TR

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            May 04, 2023

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Glaukos

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Glaukos

                            U.S.A arrow
                            Cophex
                            Not Confirmed

                            Glaukos

                            U.S.A arrow
                            Cophex
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Glaukos Submits New Drug Application to U.S. FDA for iDose TR

                            Details : iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to lower intraocular pressure. Once all the travoprost is released, the iDose TR is then removed and replaced with a new iDose TR, thus offers a dropless alternative to dail...

                            Product Name : iDose TR

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            February 27, 2023

                            Lead Product(s) : Travoprost

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth